

AKI References

Special Guest: Erin Barreto, PharmD, MSc, BCPS, BCCCP, FCCM

Guidelines/Background Reading

Bellomo R, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy, and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004; 8(4): R2014-212.
<https://www.ncbi.nlm.nih.gov/pubmed/15312219>

Mehta RL, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11(2): R31.
<https://www.ncbi.nlm.nih.gov/pubmed/17331245>

Palevsky PM, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. *Am J Kidney Dis* 2013; 61(5): 649-672.
<https://www.ncbi.nlm.nih.gov/pubmed/23499048>

Kellum JA, et al. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 2013; 17(1): 204. <https://www.ncbi.nlm.nih.gov/pubmed/23394211>

Lameire N, et al. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). *Crit Care* 2013; 17(1): 205.
<https://www.ncbi.nlm.nih.gov/pubmed/23394215>

Barreto EF, et al. Prediction of the renal elimination of drugs with cystatin c vs. creatinine: a systematic review. *Mayo Clin Proc* 2019; 94(3): 500-514.
<https://www.ncbi.nlm.nih.gov/pubmed/30713050>

Studies Discussed During the Episode

Tomasev N, et al. A clinically applicable approach to continuous prediction of future acute kidney injury. *Nature* 2019; 572(7767): 116-119.
<https://www.ncbi.nlm.nih.gov/pubmed/31367026>

- Malhotra R, et al. A risk prediction score for acute kidney injury in the intensive care unit. *Nephrol Dial Transplant* 2017; 32(5): 814-822. <https://www.ncbi.nlm.nih.gov/pubmed/28402551>
- Pajenda S, et al. NephroCheck data compared to serum creatinine in various clinical settings. *BMC Nephrol* 2015; 16: 206. <https://www.ncbi.nlm.nih.gov/pubmed/26651477>
- Kane-Gill SL, et al. Clinical relevance and predictive value of damage biomarkers of drug-induced kidney injury. *Drug Saf* 2017; 40(11): 1049-1074. <https://www.ncbi.nlm.nih.gov/pubmed/28674842>
- Barreto EF, et al. Innovative use of novel biomarkers to improve the safety of renally eliminated and nephrotoxic medications. *Pharmacotherapy* 2018; 38(8): 794-803. <https://www.ncbi.nlm.nih.gov/pubmed/29883532>
- Mårtensson K, et al. The rise and fall of NGAL in acute kidney injury. *Blood Purif* 2014; 37(4): 304-310. <https://www.ncbi.nlm.nih.gov/pubmed/25170751>
- Meersch M, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med* 2017; 43(11): 1551-1561. <https://www.ncbi.nlm.nih.gov/pubmed/28110412>
- Kellum JA, et al. The handwriting is on the wall: there will soon be a drug for AKI. *Nat Rev Nephrol* 2019; 15(2): 65-66. <https://www.ncbi.nlm.nih.gov/pubmed/30546091>
- Pai MP, et al. Antimicrobial dosing considerations in obese adult patients. *Pharmacotherapy* 2007; 27(8): 1081-1091. <https://www.ncbi.nlm.nih.gov/pubmed/17655508>
- Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. *Adv Chronic Kidney Dis* 2010; 17(5): e53-62. <https://www.ncbi.nlm.nih.gov/pubmed/20727504>
- Stevens LA, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. *Am J Kidney Dis* 2009; 54(1): 33-42. <https://www.ncbi.nlm.nih.gov/pubmed/19446939>
- Chen S. Retooling the creatinine clearance equation to estimate kinetic GFR when the plasma creatinine is changing acutely. *J Am Soc Nephrol* 2013; 24(6): 877-888. <https://www.ncbi.nlm.nih.gov/pubmed/23704286>
- Inker LA, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Eng J Med* 2012; 367(1): 20-29. <https://www.ncbi.nlm.nih.gov/pubmed/22762315>

Frazeo EN, et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. *Crit Care* 2014; 18(3): R110.

<https://www.ncbi.nlm.nih.gov/pubmed/24887089>

Frazeo E, et al. Cystatin c-guided vancomycin dosing in critically ill patients: a quality improvement project. *Am J Kidney Dis* 2017; 69(5): 658-666.

<https://www.ncbi.nlm.nih.gov/pubmed/28131530>

Pais GM, et al. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and confirmatory cellular model. *J Antimicrob Chemother* 2020 Feb 3. pii: dkz563. doi: 10.1093/jac/dkz563. [Epub ahead of print].

<https://www.ncbi.nlm.nih.gov/pubmed/32011685>

Schreier DJ, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal beta lactams with vancomycin. *Clin Infect Dis* 2019; 68(9): 1456-1462. <https://www.ncbi.nlm.nih.gov/pubmed/30165426>

Luther MK, et al. Vancomycin plus piperacillin/tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. *Crit Care Med* 2018; 46(1): 12-20.

<https://www.ncbi.nlm.nih.gov/pubmed/29088001>

Martin GS, et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2005; 33(8): 1681-1687.

<https://www.ncbi.nlm.nih.gov/pubmed/16096441>

Weisbord SD, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. *N Eng J Med* 2018; 378(7): 603-614. <https://www.ncbi.nlm.nih.gov/pubmed/29130810>